The following is a summary of the Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript:
Financial Performance:
Collegium reported record total net product revenues of $159.3 million in Q3 2024, up 17% year-over-year.
Adjusted EBITDA was a record $105.1 million, up 18% year-over-year.
Financial growth was particularly strong in the Pain portfolio, and Jornay PM is expected to generate over $100 million in net revenue in 2024.
Business Progress:
Completed the acquisition of Ironshore, integrating Jornay PM into the ADHD market.
Jornay PM prescriptions increased 31.2% year-over-year, highlighted by back-to-school season growth.
Introduced new CEO Vikram Karnani, a seasoned biopharmaceutical executive, to lead future growth and expansion.
Opportunities:
Integration of Ironshore's Jornay PM broadens Collegium's commercial presence into the large ADHD market, enhancing revenue diversification beyond pain management.
Risks:
No explicit risks detected.
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
